A 2026 preprint following 964 adults who used a Chicago mobile medical unit for opioid use disorder care found 5 follow-up patterns over 12 months: 56% made 1 visit, while the remaining patients showed slow decline, fast decline, infrequent use, or continued use.1 Research Highlights The cohort was large for mobile OUD care: 3,528 OUD-related …
A 2026 randomized youth trial found that integrated exposure-based treatment reduced posttraumatic stress disorder symptoms more than supportive counseling, while substance-use changes were smaller and showed no clear treatment-specific advantage. Research Highlights COPE-A reduced PTSD more: youth receiving Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure – Adolescent version had a 17.00-point …
A 2026 cross-sectional school study involving 1,848 rural Thai teenagers found that 17.6% reported a tendency to use e-cigarettes, even though Thailand bans e-cigarette sale and importation.1 The strongest adjusted correlate was having ever considered smoking cigarettes: those teenagers had 6.71 times the odds of e-cigarette use tendency compared with teenagers who had never considered …
A 2026 laboratory study found no detectable acute-pain increase in frequent cannabis users after at least 12 hours of biochemically verified abstinence. Frequent users had higher THC exposure and higher plasma cannabinoid markers, but pain threshold, pain tolerance, and pain ratings did not differ from occasional users.1 Research Highlights 75 healthy adults were tested: Pabon …
A 2026 study involving 32 adult mangrove rivulus fish pairs found that 3,000 µg/L waterborne psilocybin reduced movement and aggressive swimming bursts, but the result belongs in animal behavioral pharmacology, not in human aggression treatment claims.1 Research Highlights Fish movement decreased: psilocybin produced a treatment-by-time interaction for time spent moving (p = 0.006), with a …
A 2026 medRxiv preprint interviewed 15 health-system stakeholders about CARES, a freestanding addiction-risk screening platform, and found a clear implementation split: people wanted better substance-use prevention tools than current clinic screening, but provider burden, stigma, knowledge gaps, and medical-record liability could block uptake.1 Research Highlights Stakeholders saw a screening gap: all 15 interviewees held leadership …
A Global Burden of Disease analysis estimated that U.S. age-standardized substance-use disorder disability-adjusted life-year rates rose 213.5% from 1990 to 2019, with opioid use disorders producing the steepest increase and the largest state-level burden.1 Research Highlights U.S. cases rose sharply: prevalent substance-use disorder cases increased from 12.6 million in 1990 to 19.5 million in 2019.1 …